- Home
- BBIO vs TOL Comparison
BBIO vs TOL Comparison
Compare BBIO & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | TOL |
|---|---|---|
| Founded | 2015 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.9B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | BBIO | TOL |
|---|---|---|
| Price | $69.97 | $164.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 17 |
| Target Price | $86.33 | ★ $164.44 |
| AVG Volume (30 Days) | ★ 2.7M | 1.0M |
| Earning Date | 05-12-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 0.72% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 4.91 |
| Revenue | $502,076,000.00 | ★ $7,143,258,000.00 |
| Revenue This Year | $89.45 | N/A |
| Revenue Next Year | $73.78 | $6.01 |
| P/E Ratio | ★ N/A | $32.75 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $41.80 | $113.25 |
| 52 Week High | $84.94 | $168.36 |
Technical Indicators
Market Signals| Indicator | BBIO | TOL |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 69.75 |
| Support Level | $62.94 | $129.24 |
| Resistance Level | $71.74 | $168.36 |
| Average True Range (ATR) | 2.24 | 5.31 |
| MACD | 0.44 | 1.91 |
| Stochastic Oscillator | 84.55 | 96.73 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Toll Brothers consistently ranks as a top 10 builder within the US according to total home closings. Traditional homebuilding operations represent most of the company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.